61619
document
Japan useful medication program for schizophrenia ( JUMPs ) -long-term study on discontinuation rate , resolution and remission , and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia . BACKGROUND It is desirable to establish evidence for the selection of antipsychotics from the viewpoint of recovery of social activity in individual patient with schizophrenia receiving medication . From this perspective , awareness of the importance of studies about drug effectiveness on treatment discontinuation rate , remission rate , and improvement in QOL has grown recently . In Western countries , numerous reports are available in effectiveness studies , which are related to olanzapine and risperidone primarily , whereas evidence for other second-generation antipsychotics ( SGAs ) is poor . In Japan , no effectiveness study has been reported : thus , it is desirable to collect data that will serve as evidence for selection of the 3 SGAs approved after olanzapine . METHODS The present study was a long-term effectiveness study under healthcare setting in Japan . It was designed as an open-label , multicenter , randomized , comparative study involving 104-week oral treatment with 1 of the 3 drugs ( aripiprazole , blonanserin , and paliperidone ) in patients with schizophrenia aged 20 years or over who required antipsychotic medication or switching of the current medication to others for reasons such as lack of efficacy and intolerability . The primary endpoint is treatment discontinuation rate for any causes . The secondary endpoints include remission rate , improvement of social activity , alleviation , aggravation or recurrence of psychiatric symptoms , and safety . The target number of subjects was set at 300 . DISCUSSION Because this study is expected to yield evidence regarding the selection of antipsychotics for facilitating the recovery of social activity in patients with schizophrenia , it is considered highly valuable to perform this effectiveness study under ordinary healthcare setting in Japan . TRIAL REGISTRATION UMIN Clinical Trials Registry 000007942 .
61620
Intervention_Pharmacological
atypical antipsychotic medications
61621
Intervention_Pharmacological
antipsychotics
61622
Intervention_Pharmacological
aripiprazole
61623
Intervention_Pharmacological
blonanserin
61624
Intervention_Pharmacological
paliperidone
61625
Intervention_Pharmacological
antipsychotic medication
61626
Outcome_Mental
treatment discontinuation rate for any causes
61627
Outcome_Physical
remission rate
61628
Outcome_Mental
improvement of social activity
61629
Outcome_Physical
alleviation
61630
Outcome_Mental
aggravation or recurrence of psychiatric symptoms
61631
Outcome_Other
safety
61632
Participant_Condition
schizophrenia
61633
Participant_Condition
schizophrenia
61634
Participant_Age
aged 20 years or over
61635
Participant_Sample-size
300
61636
Participant_Condition
schizophrenia